← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT07220733

NCT07220733 Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07220733
Status Recruiting
Phase Phase 1, Phase 2
Sponsor Wandercraft
Condition Critical Illness
Study Type INTERVENTIONAL
Enrollment 5 participants
Start Date 2025-10
Primary Completion 2026-02

Trial Parameters

Condition Critical Illness
Sponsor Wandercraft
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 5
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-10
Completion 2026-02
Interventions
Self-balancing robotic exoskeleton (Atalante X)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Patients admitted to the Intensive Care Unit (ICU) after thoracic surgery often experience complications related to immobility, such as muscle weakness, pulmonary issues, and longer recovery times. Early mobilization has been shown to improve outcomes, but its implementation is often limited by patient fragility and staff resources. This study will test the safety and feasibility of using the Atalante X, a self-balancing exoskeleton, in the Thoracic Surgical ICU at Brigham and Women's Hospital. The exoskeleton is designed to support patients in standing and walking, even if they have limited strength or balance, thereby reducing the physical burden on healthcare staff and increasing patient mobility. Eligible participants are adults recovering from thoracic surgery, who are debilitated (Johns Hopkins Highest Level of Mobility scale ≤ 5). Each participant will undergo up to 2-3 exoskeleton sessions per week for a maximum of 2 weeks. Sessions will be personalized, with progressive standing time and walking depending on patient tolerance. The primary goal is to evaluate the safety of exoskeleton use, measured by adverse events such as skin lesions, cardiovascular instability, or accidental device-related issues. The secondary goals are to evaluate: Feasibility (ability to deliver sessions as planned, duration of standing/walking, level of assistance needed), Usability (patient and staff satisfaction, ease of donning/doffing, staff workload), and Preliminary effectiveness (improvement in mobility scores at discharge). Results will provide early insights into whether robotic exoskeletons can be safely integrated into ICU rehabilitation programs after thoracic surgery.

Eligibility Criteria

Inclusion Criteria: * Above age of 18 years old, * Having undergone thoracic surgery that necessitated admission in the TSICU. * Debilitated as defined as a JH-HLM score of 5 or less Exclusion Criteria: * Height \< 6'3 feet or weight \> 220 lbs restrictions * Severe muscular spasticity of the lower extremities (Modified Ashworth Scale Grade 3 higher). * Current fractures or incomplete bone junctions in the spine, pelvis, and/or lower extremities * Osteoporosis or lower bone mineral density -3.5, and history(ies) of osteoporotic fracture(s). * Skin disorders including Stage I pressure injuries at the hip, lower limbs, and Exoskeleton contact areas, according to the National and European Pressure Ulcer Classification System (NPUAP-EPUAP). * Severe arthritis, acute arthritis, or synovitis after total or partial lower limb joint replacement. * Myocardial infarction or angina or ischemic heart disease within the last 6 months. * Uncorrectable leg length discrepancy over 2 cm when using addi

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology